Skip to main content

Table 1 General demographics and clinical characteristics of study arms

From: Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

 

Gemcitabine

Gemcitabine + nab-P

p

Median [range]

Median [range]

Age (years)

65.5 [37–78]

62 [26–76]

0. 031

 

n (%)

n (%)

p

Sex

  

0. 911

Male

38 (60.3)

38 (61.3)

 

Female

25 (39.7)

24 (38.7)

 

Localization

  

0. 325

Head

25 (40.3)

27 (45)

 

Head + corpus

8 (12.9)

4 (6.7)

 

Corpus

11 (17.7)

11 (18.3)

 

Corpus + tail

5 (8.1)

7 (11.7)

 

Tail

7 (11.3)

10 (16.7)

 

Response

  

0. 009*

CR

2 (3.4)

–

 

PR

12 (20.3)

23 (37.1)

 

SD

20 (33.9)

27 (43.5)

 

PD

25 (42.4)

12 (19.4)

 
  1. *Rate of progressive disease is responsible from the difference
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us